fiscal impacts of prophylactic mastectomies and breast reconstructions on our health care system. With an estimated 232,430 diagnoses of breast cancer in 2013, up to 10 percent of which are in BRCA mutation carriers, the economic implications of prophylactic mastectomy carry significant weight. 2 This topic is timely for many health care providers and policy makers. Given the dearth of data comparing the lifetime costs of surveillance versus contralateral or bilateral prophylactic mastectomy with immediate reconstruction, we aim to estimate their financial implications. Of those studies that evaluated contralateral and bilateral prophylactic mastectomy costs in some way previously, many have concluded that riskreduction operations can be cost-saving. Since the Women's Health and Cancer Rights Act of 1998, breast reconstruction costs of both breasts, including the opposite breast if performed for symmetry, are covered by third-party payers. Therefore, understanding the fiscal impact of this coverage has become increasingly timely.
Contralateral prophylactic mastectomies were previously evaluated by Zendejas et al., who calculated a cost of $4869 per quality-adjusted lifeyear. 3 Values below $50,000 per quality-adjusted life-year have traditionally been accepted as costeffective. A recent cost-utility study also estimated that the average patient undergoing contralateral prophylactic mastectomy would spend $279 less than those pursuing surveillance over 38 years, but estimated that there would be 0.2 qualityadjusted life-year lost, leading to a slightly suboptimal outcome. 4 The study assumed that some of the patients would undergo reconstruction. A retrospective study comparing 24 months of costs after contralateral prophylactic mastectomy and no contralateral prophylactic mastectomy, using claims data, found that among its subset of patients, contralateral prophylactic mastectomy was more expensive, with a mean difference of $6528 between the two groups for immediate contralateral prophylactic mastectomy. 5 However, the retrospective analysis included delayed contralateral prophylactic mastectomy also, and reconstructions occurring within 6 months of the mastectomy were considered immediate, so the model may lead to different conclusions if therapeutic mastectomy and contralateral prophylactic mastectomy were performed on the same day.
One cost-utility study reached the conclusion that bilateral prophylactic mastectomy with bilateral salpingo-oophorectomy costs as little as $100 per quality-adjusted life-year gained. 6 Bilateral prophylactic mastectomy with bilateral salpingo-oophorectomy had a survival advantage in another study, increasing quality-adjusted life-years with a maximum cost of $1277 per quality-adjusted life-year. 7 Bilateral prophylactic mastectomy and bilateral salpingo-oophorectomy were even estimated to be cost-saving compared with tamoxifen chemoprevention or regular surveillance. 8 When factoring in indirect costs and productivity gains, bilateral prophylactic mastectomies are thought to realize greater cost savings. 9 Among the contralateral prophylactic mastectomy studies, only one evaluated lifetime costs and reconstructive options, but did not include the growing use of single-stage implant reconstruction as an option, whereas none of the bilateral prophylactic mastectomy studies even considered the reconstructive options in the lifetime cost estimates. 4 Given that patients have different reconstructive preferences that impact their quality of life, appropriate follow-up, likelihood of reoperation, and lifetime cost estimates, it is critical to evaluate the mastectomies and reconstructions concurrently. In addition, to fully evaluate the economic impact of each choice, it is also important to estimate the present value of those costs. To do so, future costs must be discounted at a specific percentage annually to account for the time value of money, including its annual interest-earning potential in other investments. Present values are necessary in all resource allocation decisions.
This study estimates the lifetime costs and present values of surveillance versus prophylactic mastectomies among different reconstruction methods. Furthermore, we estimated the lifetime fiscal implications of the increasing use of prophylactic mastectomy in high-risk patients. We hypothesized that the increased initial costs of prophylactic mastectomies would lead to potential cost savings by reducing the need for additional future screening and treatments.
PATIENTS AND METHODS

Reimbursements
This study has been reviewed and approved by the Massachusetts General Hospital Institutional Review Board. Physician, anesthesia, hospital, and ambulatory surgery center Medicare reimbursements were used to estimate the lifetime third-party payer costs per patient of choosing surveillance or prophylactic mastectomy, for patients with a recent diagnosis of unilateral breast cancer considering contralateral prophylactic mastectomy or for BRCA gene carriers considering bilateral prophylactic mastectomy. Patients that underwent therapeutic or prophylactic mastectomy were modeled to undergo immediate breast reconstruction with either single-stage implant, expander, or abdominal perforator free flap [deep inferior epigastric perforator (DIEP)] reconstruction. For contralateral groups, only marginal reimbursements beyond the expected current and future treatment costs for unilateral breast cancer were considered. Physician reimbursements were estimated using Medicare's publicly available fee schedules, using Current Procedural Terminology and Healthcare Common Procedure Coding System codes. 10 The same codes were also used to look up costs of acellular dermal matrices and implants. Medicare's national index reimbursement level was used. All reimbursements are in 2013 U.S. dollars. Anesthesia reimbursements were estimated using base units, time units, and the 2013 conversion factor ($21.92 11 Each Diagnosis-Related Group encapsulates a group of hospitalizations expected to have similar resource use and equal reimbursement. 12 The Outpatient Prospective Payment System was used to model appropriate follow-up procedures in ambulatory surgery centers. Billing codes used are listed in Table 1 . Given the variability in billing for chemotherapy and irradiation, their reimbursement costs were estimated using previously published figures. 13 End-of-life costs and indirect costs were not estimated.
Cost Models
Twelve cost models were constructed, with each model measuring either contralateral or bilateral patients, starting with surveillance or risk reduction, and ultimately choosing to reconstruct their breasts with a direct-to-implant, tissue expander, or DIEP flap-based approach. Decision tree models were built for each group. A weighted cash flow analysis was created for each tree, using the probabilities of each event to determine how much the cost or present value of each event contributed to the weighted averages.
Each surveillance group had its respective estimate of the percentage of patients who would require mastectomy, based on published cancer incidence rates. 3, 14 Each group had its appropriate screening, preoperative workup, procedures, follow-up care, and revisions modeled using the National Comprehensive Cancer Network guidelines. [15] [16] [17] For situations without established guidelines, our institution's standard of care was used. We modeled patients considering contralateral prophylactic mastectomy that met high-risk criteria (20 percent lifetime risk of breast cancer with risk models) that make it appropriate to choose contralateral prophylactic mastectomy. Decision trees spanned 30 years at 5-year intervals (Fig. 1 ). Assumptions were as follows: prophylactic mastectomy patients underwent surgery in year 1. Each group's rate of reoperation for complications, aesthetic revisions, and implant exchanges were modeled long term based on literature estimates. All mastectomies were skin-sparing, and reconstructions included nipple-areola complex reconstruction. Follow-up procedures were completed in ambulatory surgery centers. Recurrences were treated with excision and irradiation if the patient had not previously received it. Breasts that developed cancer with prior prophylactic mastectomy were reconstructed with tissue expanders. Risk of death caused by breast cancer was built into the model. All assumptions are presented in Tables 2  and 3 . [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] The Medical Care Services Index, the component of the Consumer Price Index that includes professional health services and hospital services, was used to estimate the yearly inflation-adjusted growth rate in reimbursements. 32 The yearly inflation-adjusted reimbursement increase averaged 1.63 percent from 2003 to 2013; thus, an estimate of 1.5 percent was used in our baseline models. 33 An annual 3 percent discount rate was then applied to calculate the present value of reimbursements over 30 years.
Sensitivity Analysis
The annual inflation-adjusted reimbursement growth rate was varied from 0 to 3 percent. The discount rate was varied from 0 to 7 percent, as is the standard. 34 Another sensitivity analysis was also performed that simultaneously varied many of the inputs that could lower the price of surveillance compared with prophylactic mastectomy, to assess how the cost differences would change in scenarios more favorable for surveillance.
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RESULTS
Lifetime Reimbursements
In patients with unilateral breast cancer, lifetime costs (1.5 percent growth, 0 percent discount rate) were higher by $1292 to $1993 in surveillance versus contralateral prophylactic mastectomy, whereas present value (1.5 percent growth, 3 percent discount rate) was $132 to $601 less expensive in surveillance than with contralateral prophylactic mastectomy. Patients considering bilateral prophylactic mastectomy had a wider variability in their totals. Lifetime costs were higher for surveillance than for bilateral prophylactic mastectomy patients, ranging from $15,668 to $21,342 more throughout each patient's life. In present-value terms, bilateral prophylactic mastectomy would save between $4835 and $8003 compared with surveillance.
Sensitivity Analysis
Sensitivity analysis of the discount rate and the growth rate is presented in Tables 4 and 5 . For contralateral prophylactic mastectomy patients, contralateral prophylactic mastectomy was cost-saving when comparing lifetime costs across all growth rates, but was generally slightly more expensive when the discount rate was not 0 percent. However, both lifetime cost and present-value terms were cost-saving for contralateral prophylactic mastectomy if the predicted incidence of developing breast cancer in the contralateral breast was 0.6 percent per year or higher. For BRCA patients, lifetime costs and present values for bilateral prophylactic mastectomy were lower than for surveillance. Trends observed for both models were that as discount rate increased and growth rate decreased, the more favorable surveillance would be relative to prophylactic mastectomy, and vice versa. The other sensitivity analysis involved changing multiple variables in each model simultaneously, and is presented in Tables 2 and 3 . Even after all simultaneous variable changes, the lifetime costs of contralateral patients remained higher for surveillance and the present values remained lower. In the bilateral patients, lifetime costs remained lower but the present value of DIEP reconstruction is the only reconstructive option that remained less expensive than its surveillance counterpart.
DISCUSSION
Patients increasingly seek more proactive ways of reducing their risk of breast cancer. In patients with lobular carcinoma in situ, a risk marker for breast cancer, the rate of bilateral prophylactic mastectomy has recently increased by 50 percent. 35 More information is needed regarding the impacts of prophylactic mastectomy trends on lifetime costs of treatment. To our knowledge, this analysis is unique in estimating the lifetime costs of contralateral prophylactic mastectomy with direct-to-implant reconstruction, as prior work has reported the cost only of staged implant reconstruction. Furthermore, we report on the impact of reconstruction on lifetime bilateral prophylactic mastectomy costs. Our results suggest that contralateral and bilateral prophylactic mastectomies with immediate reconstruction may be cost-saving throughout a lifetime, and comparable in present-value terms. Contralateral prophylactic mastectomies become cost-saving in presentvalue terms when the incidence of contralateral breast cancer exceeds 0.6 percent per year, which suggests that for high-risk patients, prophylactic mastectomies do not increase the fiscal impact of health care.
For contralateral prophylactic mastectomy patients, most of the necessary testing, office visits, and hospitalizations can be performed when treating the unilateral malignancy, making the simultaneous treatment of the contralateral breast more inexpensive than treatment of the index breast. Only a few additional costs have to be added to the already expected treatment costs for unilateral mastectomy. Meanwhile, contralateral surveillance leads to separate hospitalizations, anesthesia, and operations if contralateral cancer develops. Therefore, although only a small percentage of patients develop contralateral cancer, the difference in cost of simultaneous contralateral prophylactic mastectomy versus separate hospitalizations and procedures for contralateral breast cancer treatment makes the average cost per patient for both comparable.
For patients that decide to pursue a contralateral prophylactic mastectomy after a prior therapeutic mastectomy, these cost estimates do not apply, as separate hospitalizations and operations add significantly to the estimates. In bilateral prophylactic mastectomy, the savings incurred after risk reduction were mostly through the avoidance of future yearly magnetic resonance imaging scans and mammograms that all high-risk patients face, and the significantly lower likelihood of requiring radiation therapy and chemotherapy after bilateral prophylactic mastectomy than after therapeutic mastectomy.
These findings further corroborate the findings in prior studies that contralateral prophylactic mastectomy and bilateral prophylactic mastectomy can both be comparable in cost to surveillance. Perhaps most different from prior estimates is the cost of mastectomy with free flap reconstruction, which in our study was only $24,408 but in prior estimates has been as high as $56,205.
36 A large part of the difference is likely because that study used mostly private insurance claims made for breast reconstruction, which often have reimbursement rates significantly higher than those of Medicare. In addition, the patients included in the study were not necessarily prophylactic mastectomy patients, and therefore had higher rates of radiation therapy, among other cost-intensive measures. The reality is likely between these two estimates.
If efforts to diminish the cost growth of health care are effective, as the sensitivity analysis shows, surveillance would become less expensive relative to prophylactic mastectomy. Long-term costs of surveillance and prophylactic mastectomy are similar because prophylactic mastectomies diminish the need for future magnetic resonance imaging scans, mammograms, biopsies, and higher cost therapeutic mastectomies. Patients undergoing therapeutic mastectomies are also more likely to undergo radiation therapy and revisions. 37 However, both the positive and negative effects of prophylactic mastectomy on quality of life must be considered. Prophylactic mastectomies increase the likelihood of being eligible for nipple-sparing mastectomy, which can improve aesthetic results and patient satisfaction after surgery. 38 Younger patients after bilateral prophylactic mastectomy also rarely need chemotherapy. Nonetheless, prophylactic mastectomies may result in poor outcomes, decreased sexual functioning, and postmastectomy pain syndromes, which must be discussed openly with patients. 39 In addition, some patients can alternatively reduce their breast cancer risk by 50 percent with tamoxifen instead of surgery.
The modeling of Medicare's lifetime reimbursements for each group has multiple limitations. As is true of all models, ours are simplified versions of reality. We attempted to create models that represent the average patient, but given the variability in the procedures, rates of reoperation, and other factors, it is impossible to represent them perfectly. For example, when a patient is admitted for a DIEP free flap reconstruction, the length of stay is 2 to 3 days longer on average than for implant or expander reconstructions, but that difference is not captured by the Diagnosis-Related Group code used for mastectomies.
Therefore, in reality, the costs of DIEP reconstructions are underestimated in our model. Terminal life costs, which can be over $70,000 in the last 6 months of life, were not included. 40 We took the third-party payer's perspective, not the societal perspective, which would include indirect costs and is the ideal method of calculation. Another component not covered that would benefit from further study is patient preference, to better inform us about cost utility through quality-adjusted life-year impacts. Finally, the rates of revisions, complications, chemotherapy, and other factors may vary from the rates found in the literature. Our sensitivity analyses, which show the prophylactic mastectomies to be at least comparable in cost even in surveillance-favoring scenarios, provide further evidence that our models reach reasonable estimates. These estimates are mostly applicable to hospitals and regions where immediate reconstruction with at least one of the modeled options is available. We chose to model costs based on the national index reimbursement rate for Medicare for multiple reasons. First and foremost, given that most private insurance companies benchmark their reimbursement rates using the relative value units produced by Medicare, it is a common denominator in terms of cost. Although the absolute values may differ significantly between Medicare and private payers, the relative reimbursement differences between procedures within Medicare and any private payer should be proportional. Moreover, we felt that Medicare reimbursement rates would be more representative of the true resource costs, whereas private insurance reimbursements are more likely aligned with hospital charges but not necessarily resource costs. Given the significant variability in reimbursement by region, insurance company, and hospital, we wanted to choose a source of cost estimates that would estimate more accurately the national fiscal impact, if not in absolute value, then at least in relative value. Therefore, these results should be interpreted more in terms of their relative impact on fiscal health care spending than as representative 
